PhRMA counterfeit reporting program
Executive Summary
Pharmaceutical Research & Manufacturers of America member companies will notify FDA Office of Criminal Investigations of suspected counterfeit drugs "within five working days" under voluntary agreement announced April 22. Program was developed by PhRMA's FDA Key Issues Committee and will go into effect May 1. FDA and PhRMA will assess the program for possible improvements after one year, agency says...
You may also be interested in...
Pfizer Lipitor counterfeit crackdown
Pfizer directs FDA to three lots of counterfeit Lipitor (atorvastatin) recalled by Albers Medical Distributors. Pfizer's help is part of an agreement between Pharmaceutical Research & Manufacturers of America member companies and FDA that companies will alert FDA Office of Criminal Investigations of suspected counterfeit drugs within five working days (1"The Pink Sheet" April 28, 2003, In Brief)...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: